Evidence map›Paper›PMID 41354851›Full record

ArticleNature communications2025

Aberrant adenosine A

Wu Zheng, Lanxin Hu, Yuwen Yang, Xuhang Li, Jia Wu, Wangchao Chen, Yiwei Jiang, Yuhan Chen, Hongcai Wang, Shiwei Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Adenosine APurinergic signalling · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wu Zheng *The Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. zheng123wu@163.com.ORCID http://orcid.org/0000-0002-5091-9694
Lanxin Hu *The Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yuwen Yang *The Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xuhang LiThe Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jia WuKey Laboratory for Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Wangchao ChenThe Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yiwei JiangThe Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yuhan ChenThe Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Hongcai WangDepartment of Neurosurgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China.
Shiwei LiDepartment of Neurosurgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China.
Kuan FengDepartment of Neurosurgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China.
Cheng ZhengThe Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yanjiang WangThe Department of Neurology, Daping Hospital, The Arm Medical University, Chongqing, China.
Rodrigo A CunhaCNC-Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.ORCID http://orcid.org/0000-0003-2550-6422
Zhongyue LvDepartment of Neurology, the Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China. lzy_neuro@163.com.ORCID http://orcid.org/0000-0002-8906-0629
Jiang-Fan ChenThe Eye-Brain Research Center and Molecular Neuropharmacological Lab, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. chenjf555@gmail.com.ORCID http://orcid.org/0000-0002-0446-3956

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrocephalus is a common and serious neuropathological condition characterized by disrupted cerebrospinal fluid (CSF) circulation, which lacks effective pharmacotherapy. Here, we demonstrate that adenosine A

Indexed as

Cerebrospinal FluidChoroid PlexusHydrocephalusReceptor, Adenosine A2AAdenosineAdenosine A2 Receptor AntagonistsAnimalsDisease Models, AnimalFemaleHumansKaolinMaleMiceMice, Inbred C57BLMice, TransgenicPhosphatidylinositol 3-KinasesAdenosineAdenosine A2 Receptor AntagonistsKaolinPhosphatidylinositol 3-KinasesReceptor, Adenosine A2A

Identifiers

PMID41354851
PMCPMC12770498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.